pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$CAPRCAPRICOR THERAPEUTICS, INC.

$CAPR9.0000+4.65%
San Diego, CA, USupdated 10d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 1: 1pre_registration: 1
1Phase 11pre_registration
Phase 1
Exosome-Based Vaccine
Coronavirus Disease 2019 (COVID-19)
pre_registration
deramiocel
Cardiomyopathy

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Open-label Extension of the HOPE-2 Trialactive not recruitingn=13
  • phase3A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophyactive not recruitingn=106
  • phase2A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophycompletedn=20
  • phase2Intravenous Infusion of CAP-1002 in Patients With COVID-19completedn=55
  • phase2HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)completedn=25
  • phase2Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)completedn=8
  • phase2Allogeneic Heart Stem Cells to Achieve Myocardial Regenerationterminatedn=135
🐶 Hiring Signal
13 open roles at CAPRICOR THERAPEUTICS, INC. →

Where CAPRICOR THERAPEUTICS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaRare Disease 12Cardiovascular 1
departmentCommercial 2Market Access 2Quality 2Legal & Compliance 2Biostatistics / Data 1Supply Chain 1

News

  • Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
    Less than two weeks away from a highly anticipated FDA ruling on its cell therapy for Duchenne muscular dystrophy, Capricor Therapeutics has reported increased investment in its San Diego plant to…
    biospace · 5d ago
  • Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…
    biospace · 6d ago
  • ‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
    Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and C…
    biospace · 1mo ago
  • Capricor investor calls for change as company awaits decision on Duchenne candidate
    Kaos Capital in a letter to other Capricor Therapeutics shareholders called for “an immediate meeting, board change, and capital-preservation plan.” The biotech recently put all other pipeline work…
    biospace · 2mo ago
  • UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
    UniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by R…
    biospace · 3mo ago
  • STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
    Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
    stat · 3mo ago
identifiers
ticker
$CAPR
SEC CIK
0001133869
country
US
source
sec_tickers
top tags
Cardiology1Duchenne Muscular Dystrophy1Infectious Disease1
mentioned in
6news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 27m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?